anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An inexpensive device with a disposable cartridge for preparing tissue sealant is disclosed. The device is particularly applicable to stat preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate (from the device) with a solution of calcium and thrombin is also disclosed. Preparation in the operating room of 5 cc sealant from 50 cc patient blood requires less than 15 minutes and only one simple operator step. There is no risk of tracking error because processing can be done in the operating room. Chemicals added may be limited to anticoagulant (e.g., citrate) and calcium chloride. The disposable cartridge may fit in the palm of the hand and is hermetically sealed to eliminate possible exposure to patient blood and ensure sterility. Adhesive and tensile strengths are comparable or superior to pooled blood fibrin sealants made with precipitation methods. Antifibrinolytic agents (such as aprotinin) are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient's blood. The tissue sealant also contains patient platelets and additional factors not present in available fibrin sealants that promote wound healing.
Atherosclerosis represents the major cause of mortality worldwide and triggers higher risk of acute cardiovascular events. Pericytes-endothelial cells (ECs) communication is orchestrated by ligand-receptor interaction generating a microenvironment which results in intraplaque neovascularization, that is closely associated with atherosclerotic plaque instability. Notoginsenoside R1 (R1) exhibits anti-atherosclerotic bioactivity, but its effect on angiogenesis in atherosclerotic plaque remains elusive. The aim of our study is to explore the therapeutic effect of R1 on vulnerable plaque and investigate its potential mechanism against intraplaque neovascularization. The impacts of R1 on plaque stability and intraplaque neovascularization were assessed in ApoE-/- mice induced by high-fat diet. Pericytes-ECs direct or non-direct contact co-cultured with VEGF-A stimulation were used as the in vitro angiogenesis models. Overexpressing Ang1 in pericytes was performed to investigate the underlying mechanism. In vivo experiments, R1 treatment reversed atherosclerotic plaque vulnerability and decreased the presence of neovessels in ApoE-/- mice. Additionally, R1 reduced the expression of Ang1 in pericytes. In vitro experiments demonstrated that R1 suppressed pro-angiogenic behavior of ECs induced by pericytes cultured with VEGF-A. Mechanistic studies revealed that the anti-angiogenic effect of R1 was dependent on the inhibition of Ang1 and Tie2 expression, as the effects were partially reversed after Ang1 overexpressing in pericytes. Our study demonstrated that R1 treatment inhibited intraplaque neovascularization by governing pericyte-EC association via suppressing Ang1-Tie2/PI3K-AKT paracrine signaling pathway. R1 represents a novel therapeutic strategy for atherosclerotic vulnerable plaques in clinical application.
NEW MATERIAL:A compound of formula I [X is -O-mycinose or di(lower alkyl) amino; R<1> is H or lower alkanoyl; R<2> is lower alkyl, cycloalkyl-lower alkyl, etc.; R<3> is H or OH] or a salt thereof. EXAMPLE:9-Dihydro-9-O-methyldesmycosin. USE:An infectious disease remedy. The compound exhibits an excellent infectious disease-treating effect when orally administered. PREPARATION:The aldehyde group of a desmycosin derivative of formula II is first protected and the protected product is reduced with an alkali borohydride such as sodium borohydride in a solvent such as methanol. The prepared compound of formula III (R groups are lower alkyl, respectively, or two of the R groups form a lower alkylene) is reacted with an alcohol of a formula: R<2>-OH in the presence of an acidic catalyst, followed by removing the aldehyde-protecting group of the reaction product.
It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks \[patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)\] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
FIELD: medicine, oncology. SUBSTANCE: invention relates to method of treatment that can be used in different stages of disease. Invention proposes to use alpha-tocopherol phosphate as drug in combination with potassium iodide that are administrated to patient orally as crystalline powder or tablets. Alpha-tocopherol phosphate is prescribed in the morning, 5-15 min before breakfast in the amount 200-400 mg and depending on patient state for 3-6 months; potassium iodide is intaken immediately after breakfast in the amount 8-10 mg for 30 days. In the case of strong intoxication ascorbic acid tablets in the dose 0.5 g after eating per a day and 10% solution of ascorbic acid by intravenous route in the amount 10-50 ml are prescribed additionally. EFFECT: enhanced effectiveness of treatment. 2 cl, 3 ex
In Arm 1, bioimpedance measurements are taken by research staff. The participants also wear an ActiGraph monitor for at least one week prior to their prosthetist preforming modifications to their socket.
Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
The present invention discloses a prescription for curing cardiovascular diseases and a processing method thereof. An A prescription is mainly suitable for patients with negative cardiovascular diseases; a B prescription is mainly suitable for patients with positive cardiovascular diseases. The A prescription has the components of villous amomum fruit, atractylodes rhizome, fructusamomi rotundus, hawthorn fruit, white pepper, dried ginger, prepared common monkshood daughter root, cassia twig, coltsfoot, American ginseng, coptis, baical skullcap root, vietnamese sophora root, saffron crocus, prepared liauorice root, common aucklandia root, Chinese date, etc. The B prescription has the components of skin of abdominal wall, largehead atractylodes rhizome, medicated leaven, malt, herba agastachis, angelica, rehmannia root, cow-bezoar, tremella, tall gastrodis tuber, coptis, baical skullcap root, tuckahoe, cornel, tangshen, etc. except the fructusamomi rotundus, the hawthorn fruit, the cassia twig, the coltsfoot and the cow-bezoar, the other drugs need to be processed by the methods of cooking, soaking, steaming, etc. The present invention can be decocted by water and can also be manufactured into Chinese patent drugs such as oral medicinal liquid, tablets, granules, etc. The present invention is used for curing chronic myocardial infarction, angina pectoris, old myocardial infarction, coronary arteriosclerosis, coronary heart disease, cerebral arteriosclerosis, etc. Because of classified cure and reasonable compatibility, the present invention cures both manifestation and root cause of disease and has an obvious therapeutic effect.
After induction of general anesthesia with propofol, remifentanil and succinylcholine, the patients will be divided either in the pectoral block group or the control group (sham block). Both groups will receive the same perioperative and postoperative anesthetic protocol. The investigator in charge of the patient will leave the operative room right before the completion of the pectoral block (or the sham block) to preserve randomisation and the block will be performed by another investigator. The pectoral block is performed under ultrasound guidance with 10 cc of lidocaine 1% with epinephrine 1/400000 between the pectoralis major muscle and the pectoralis minor muscle and 20 cc of the same solution between the pectoralis minor muscle and the serratus anterior muscle at the third rib. Anesthesia will be maintained with sevoflurane for a bispectral (BIS) index between 45 and 60. Analgesia will be provided with a perfusion of remifentanil adjusted to maintain a mean arterial blood pressure (MAP) in the range of ± 10% of the basal MAP (mean of the last three MAPs obtained before surgical incision, under sevoflurane-only anesthesia). The total remifentanil consumption will be assessed and compared between the groups. The investigators believe that the pectoral nerve block will significantly reduce the intraoperative remifentanil consumption.
A bacteriophage is provided to kill pathogenic bacteria of Staphylococcus aureus specifically, thereby being widely used as an agent for preventing and treating infectious diseases caused by the Staphylococcus aureus, antibiotics, an antibacterial agent for cosmetics or a preservative derived from nature, and various disinfectants. A Myoviridae family T4-like phage genus bacteriophage has the killing activity specific to Staphylococcus aureus, comprises a genetic body including a nucleic acid molecule described as sequences consisting of SEQ ID : NOs. 1 to 26 and is deposited as a deposition no. KACC 97001P. A pharmaceutical composition for preventing or treating diseases induced by Staphylococcus aureus comprises the bacteriophage as an effective ingredient. An antibiotic or a disinfectant comprises the bacteriophage as an effective ingredient.
INTRODUCTION: Muscle health in diabetes mellitus (DM) is often neglected, which leads to muscle wasting. Increased reactive oxygen species in DM could decrease antioxidant enzymes such as superoxide dismutase-1 (SOD-1) and -2 (SOD-2) and inhibit calcineurin (CN) and PGC-1α signalling pathways. Chlorogenic acid (CGA) is known as a potent antioxidant and activators of CN and PGC-1α. This study aimed to determine the effect of CGA on mRNA expressions of SOD-1, SOD-2, CN and PGC-1α in inhibiting the progression of DM to muscle wasting.
MATERIALS AND METHODS: This study was conducted at Department of Anatomy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada starting on July 20th, 2020. A total of 24 male Wistar rats were randomly divided into six groups (four rats per group), i.e., control, DM 1.5 months (DM1.5), and DM 2 months (DM2); and DM groups treated with CGA in three different doses, namely CGA1 (12.5 mg/kg BW), CGA2 (25 mg/kg BW), and CGA3 (50 mg/kg BW). Control group was only injected with normal saline, while diabetic model was induced by intraperitoneal injection of streptozotocin. Blood glucose levels were measured twice (one week after diabetic induction and before termination). The soleus muscle tissue was harvested to analyse the mRNA expressions of SOD-1, SOD- 2, CN and PGC-1α using RT-PCR. In addition, the tissue samples were stained with immunohistochemistry for CN and haematoxylin-eosin (HE) for morphologic analysis under light microscopy.
RESULTS: The mRNA expressions of SOD-1 and SOD-2 in the CGA1 group were relatively higher compared to the DM2 groups. The mRNA expression of CN in the CGA1 group was significantly higher compared to the DM2 group (p = 0.008). The mRNA expression of PGC-1α in the CGA1 group was significantly higher compared to the DM2 group (p = 0.025). Immunohistochemical staining showed that CNimmunopositive expression in the CGA1 group was more evident compared to the other groups. Haematoxylin-eosin staining showed that muscle tissue morphology in the CGA1 group was similar to that in the control group.
CONCLUSION: Chlorogenic acid at a dose of 12.5 mg/kg BW shows lower blood glucose level, good skeletal muscle tissue morphology and higher mRNA expressions of SOD-1, SOD-2, CN and PGC-1α compared to the DM groups.
A device for delivering an anesthetic to the eye, comprising a thin, porous, substantially planar annular body. The inner diameter of the device is slightly greater than the diameter of the limbus or corneal-scleral junction of the eye, and the outer diameter, slightly smaller than the arcuate distance between the upper and lower conjunctival sacs. The device is made of a flexible material such as methylcellulose-based filter paper, thus, it is able to flex to conform to the shape of the eyeball. The device is positioned in the eye with the inner edge circumscribing the limbus and the outer edge extending into the conjunctival sacs. A liquid such as a topical anesthetic, antibiotic, and so forth is added to the body by means of an eye dropper or other suitable means. The liquid spreads rapidly and uniformly throughout the body and diffuses into the eye. If desired, a plurality of equally-spaced radial slits may be formed in the body to enable it to conform to the shape of the eye.
Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. The compositions and methods of the present invention do not require the use of α-1 general or selective antagonists and improve night vision with reduced or eliminated side effects, as compared to conventional methods. In some embodiments of the invention, the selective a-2 adrenergic receptor agonists have binding affinities (Ki) for α-2 over α-1 receptors Of 500:1 or greater. In preferred embodiments of the invention, the selective α-2 adrenergic receptor agonists have Ki for α-2 over α-1 receptors of 900:1 or greater, more preferably 1000:1 or greater, and mostpreferably, 1500:1 or greater.
Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
Adult patients with septic shock, admitted to ICUs at Hvidovre and Bispebjerg Hospital, respectively. Sedated and mechanically ventilated adult patients (\>18 years).
The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering the antibiotic concentration in serum and tissue.

Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided.

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.

Neuromuscular blockade and respiratory paralysis have been reported in the cat receiving high doses (40 mg/kg) of gentamicin. The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuro-muscular blocking agents, such as succinylcholine, tubocurarine, or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse it.

Although the in vitro mixing of gentamicin and carbenicillin results in a rapid and significant inactivation of gentamicin, this interaction has not been demonstrated in patients with normal renal function who received both drugs by different routes of administration. A reduction in gentamicin serum half-life has been reported in patients with severe renal impairment receiving carbenicillin concomitantly with gentamicin.

Probenecid does not affect renal tubular transport of gentamicin.
Patients are assigned to one of four groups. Three dose groups receive a background antiretroviral regimen (ABC, APV, RTV, and EFV) and T-20, which is given at one of three doses on a twice-daily regimen. The fourth group (control) receives the background antiretroviral regimen alone. For each treatment group, 17 patients are enrolled. Treatment is administered for 16 weeks, followed by a 32-week treatment extension, and a 2-week follow-up period. The following are assessed throughout the trial: safety parameters (as measured by hematology, clinical chemistry, urinalysis, and treatment-emergent adverse events); virologic and immunologic activity; phenotypic and genotypic resistance; T-20 plasma levels; and pharmacokinetics of T-20 and oral antiretrovirals. The total study duration is 1 year.
PROBLEM TO BE SOLVED: To obtain a cosmetic capable of efficiently improving a flabby skin in a short time and not causing problems such as skin irritation, etc., by including an astringent agent and a blood circulation promoter. SOLUTION: This cosmetic contains (A) an astringent agent and (B) a blood circulation promoter. Preferably fucus, ginseng, peach kernel, Anthemis nobilis, Ginkgo biloda or their extracts are used as the component A and tocopherol nicotinate, linden essence or horse chestnut essence as the component B. The formulated amount of the component A is 1-5 wt.% in the cosmetic and that of the component B is 0.01-3 wt.%. Preferably the addition of granule increases a massaging effect and improves a bettering effect on a flabby skin. Preferably the simultaneous addition of an oil agent for producing the skin with a glossy feeling, a bleaching agent for improving stain, etc., and a sebum secretion inhibitor improves a bettering effect on a flabby skin. Isotridecyl isononanoate or the like is preferable as the oil and kojic acid or the like as a bleaching agent.
Study population To evaluate the epidemiology and prognosis of uterine cancer in Taiwan, we will conduct a nationwide analysis through linking national cancer registry database. Every citizen in Taiwan has a life-long identification number to link individual information, including health status. The Taiwan household registry database provided by Department of Health will be the source population. National household registry and death certificate will be adopted to ascertain the live status of study subjects, and provided individual demographic characteristics. All individual linkages between databases will be conducted according to the study protocols, i.e. databases will be linked by corresponding identification number, name (Chinese characters) and birthday, and all data included in this study will be analyzed without individual identification information. The agreement of utilizing the databases in the study was obtained from the Bureau of Health Promotion in Taiwan.

Incident and death cases ascertainment Patients with uterine cancer, including uterine carcinoma, uterine sarcoma ... etc., will be identified from computerized linkage to the Taiwan national cancer registry with International Classification of Diseases for Oncology Third Edition T-code C540-C543. Histological types will be identified from morphology code in the cancer registry database. Women affected by uterine cancer and found death due to uterine cancer (International Classification of Diseases 9th edition code 182) in deaths certificate will be defined as death cases.

Statistical Analyses The numbers of person-years at risk of developing and dying for uterine cancer will be calculated. Incidence rates will be calculated by dividing the number of uterine cancer cases by the person-years at risk of developing uterine cancer. Mortality rates will be calculated by dividing the number of uterine cancer deaths by the person-years at risk of dying from uterine cancer. The association between mortality and age, histology, time periods will be estimated through Kaplan-Meier survival analysis and Cox's proportional hazards model. It is defined as significant difference statistically when p value is less than 0.05.
PURPOSE:To provide an incense stick containing crystalline cellulose, emitting little irritant smell of smoke, leaving little ash after combustion, having rich color and emitting various smell. CONSTITUTION:alpha-Cellulose is hydrolyzed with a mineral acid and the amorphous region is removed by washing. The obtained crystalline cellulose is used as a combustion-supporting agent of the objective incense stick. The crystalline cellulose has moderate combustibility, excellent retainability of perfume and white color and is almost odorless. Accordingly, it has advantages such as easy coloring, high compatibility with water, etc., and is extremely excellent as a raw material for incense stick. The amount of crystalline cellulose compounded to incense stick is 10-95wt.%, preferably 20-90wt.% based on the whole incense stick. The incense stick may be incorporated with polyvinyl alcohol as a sizing agent, sandalwood oil as a perfumery component, an organic dye as a colorant, etc., in addition to the combustion-supporting agent.
AIM: Psychotropic medication can contribute to arrhythmia and identifying individuals at risk is crucial. This Swedish study compared the corrected QT (QTc) intervals of adolescents on psychotropic medication with unmedicated controls, when supine and after rising rapidly.
METHODS: The study was carried out at Östersund County Hospital in March 2022 and February to March 2023. It comprised 16 cases, aged 10-17 years and 28 controls. QTc intervals were measured with electrocardiography and calculated using Bazett's and Fridericia's formulas. Univariate and multiple linear regressions were used to assess differences in QTc intervals between the cases and controls and across sex, age and body mass index.
RESULTS: The mean QTc interval when supine, calculated with Bazett's formula, was longer for the adolescents on psychotropic medication than the controls (p = 0.046). The same was true for the mean QTc interval after rising rapidly from the supine position, calculated with both Bazett's formula (p = 0.009) and Fridericia's formula (p = 0.007). Mean QTc intervals varied by sex and age groups. Psychotropic medication prolonged QTc intervals, particularly in girls.
CONCLUSION: Longer QTc intervals were found in adolescents on psychotropic medication, particularly after rising rapidly from the supine position.
Systems and methods for autonomously dispensing items. A dispensing system receives a first distributed ledger transaction that: i) identifies an item, ii) identifies a container associated with and containing the item, iii) includes a status indicator in a first state identifying the item as present in the container, and iv) includes an authorization code associated with a mobile device. The authorization code is received from the mobile device. The dispensing system creates a second distributed ledger transaction based on the first distributed ledger transaction that changes the status indicator to a second state identifying the item as authorized for dispensing. Responsive to the creation of the second distributed ledger transaction, access is autonomously provided to the item. The dispensing system creates a third distributed ledger transaction based on the second distributed ledger transaction that changes the status indicator to a third state identifying the item as dispensed.